Literature DB >> 21490679

Special delivery: targeted therapy with small RNAs.

D Peer1, J Lieberman.   

Abstract

Harnessing RNA interference using small RNA-based drugs has great potential to develop drugs designed to knock down expression of any disease-causing gene, thereby greatly expanding the universe of possible drug targets. However, delivering small RNAs into specific tissues and cells is still a hurdle. Here, we review recent progress in overcoming systemic, local and cellular barriers to RNA drug delivery, focusing on strategies for targeted uptake.

Mesh：

Substances：

Year:  2011        PMID： 21490679     DOI： 10.1038/gt.2011.56

Source DB:  PubMed          Journal:  Gene Ther        ISSN： 0969-7128            Impact factor:   5.250


  45 in total

Review 1.  RNA-based therapeutics: current progress and future prospects.

Authors:  John C Burnett; John J Rossi
Journal:  Chem Biol       Date:  2012-01-27

2.  Fractional thermolysis by bipolar radiofrequency facilitates cutaneous delivery of peptide and siRNA with minor loss of barrier function.

Authors:  Woan-Ruoh Lee; Shing-Chuan Shen; Chi-Kuang Sun; Ibrahim A Aljuffali; Shih-Yun Suen; Yin-Ku Lin; Jhi-Joung Wang; Jia-You Fang
Journal:  Pharm Res       Date:  2014-11-13       Impact factor: 4.200

3.  Smart Nanoscale Drug Delivery Platforms from Stimuli-Responsive Polymers and Liposomes.

Authors:  Sang-Min Lee; SonBinh T Nguyen
Journal:  Macromolecules       Date:  2013-11-27       Impact factor: 5.985

4.  Surface functionality of nanoparticles determines cellular uptake mechanisms in mammalian cells.

Authors:  Krishnendu Saha; Sung Tae Kim; Bo Yan; Oscar R Miranda; Felix S Alfonso; Denis Shlosman; Vincent M Rotello
Journal:  Small       Date:  2012-09-13       Impact factor: 13.281

5.  Toxicity profiling of several common RNAi-based nanomedicines: a comparative study.

Authors:  Dalit Landesman-Milo; Dan Peer
Journal:  Drug Deliv Transl Res       Date:  2014-02       Impact factor: 4.617

6.  Functionalized bioengineered spider silk spheres improve nuclease resistance and activity of oligonucleotide therapeutics providing a strategy for cancer treatment.

Authors:  Anna Karolina Kozlowska; Anna Florczak; Maciej Smialek; Ewelina Dondajewska; Andrzej Mackiewicz; Marcin Kortylewski; Hanna Dams-Kozlowska
Journal:  Acta Biomater       Date:  2017-07-08       Impact factor: 8.947

Review 7.  Induced protein degradation: an emerging drug discovery paradigm.

Authors:  Ashton C Lai; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2016-11-25       Impact factor: 84.694

8.  Delivery of therapeutic siRNA to the lung endothelium via novel Lipoplex formulation DACC.

Authors:  V Fehring; U Schaeper; K Ahrens; A Santel; O Keil; M Eisermann; K Giese; Jörg Kaufmann
Journal:  Mol Ther       Date:  2014-01-06       Impact factor: 11.454

9.  Fragment-based modelling of single stranded RNA bound to RNA recognition motif containing proteins.

Authors:  Isaure Chauvot de Beauchene; Sjoerd J de Vries; Martin Zacharias
Journal:  Nucleic Acids Res       Date:  2016-04-29       Impact factor: 16.971

10.  Human macrophage and dendritic cell-specific silencing of high-mobility group protein B1 ameliorates sepsis in a humanized mouse model.

Authors:  Chunting Ye; Jang-Gi Choi; Sojan Abraham; Haoquan Wu; Dolores Diaz; Daniel Terreros; Premlata Shankar; N Manjunath
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-03       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.